Maleki Ali Heidarnejad, Rajabivahid Mansour, Khosh Elnaz, Khanali Zeinab, Tahmasebi Safa, Ghorbi Mahmood Dehghani
School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Department of Internal Medicine, Valiasr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.
Clin Exp Med. 2025 Jan 11;25(1):34. doi: 10.1007/s10238-025-01562-w.
IL-27 is structurally an immune-enhancing and pleiotropic two-chain cytokine associated with IL-12 and IL-6 families. IL-27 contains two subunits, namely IL-27p28 and EBI3. A heterodimer receptor of IL-27, composed of IL27Rα (WSX1) and IL6ST (gp130) chains, mediates the IL-27 function following the activation of STAT1 and STAT3 signaling pathways. Specifically, IL-27 is identified as augmenting cytokine of immune responses, including Th1 cell differentiation, TCd4 + cell proliferation, and IFN-γ production with the help of IL-12. According to several published studies, due to the pro-inflammatory or anti-inflammatory functions of cytokine related to the biological context in various disorders and diseases, IL-27 has been considered a complex regulator of the immune system. Surprisingly, the dual role of IL-27, the same as the double-edged sword, has also been evidenced in clinical models of various hematological or solid tumors. Predominantly, Il-27 applies anti-tumor functions by inducing the responses of a cytotoxic T lymphocyte (CTL) and Th1 and suppressing the growth, proliferation, angiogenesis, invasiveness, metastasis, and survival of tumor cells. On the other hand, IL-27 may also play a protumor role in cancers and induce tumor progression. The current update study aimed to summarize the protumor anti-tumor and biological functions of IL-27 in different hematological malignancies and solid tumors.
IL-27在结构上是一种与IL-12和IL-6家族相关的免疫增强性多效性双链细胞因子。IL-27包含两个亚基，即IL-27p28和EBI3。IL-27的异二聚体受体由IL27Rα（WSX1）和IL6ST（gp130）链组成，在STAT1和STAT3信号通路激活后介导IL-27的功能。具体而言，IL-27被确定为免疫反应的增强性细胞因子，包括在IL-12的帮助下促进Th1细胞分化、TCd4 +细胞增殖和IFN-γ产生。根据多项已发表的研究，由于细胞因子在各种疾病和病症中的生物学背景相关的促炎或抗炎功能，IL-27被认为是免疫系统的复杂调节剂。令人惊讶的是，IL-27的双重作用，就像一把双刃剑，也在各种血液学或实体瘤的临床模型中得到了证实。主要地，IL-27通过诱导细胞毒性T淋巴细胞（CTL）和Th1的反应以及抑制肿瘤细胞的生长、增殖、血管生成、侵袭、转移和存活来发挥抗肿瘤功能。另一方面，IL-27在癌症中也可能发挥促肿瘤作用并诱导肿瘤进展。当前的更新研究旨在总结IL-27在不同血液系统恶性肿瘤和实体瘤中的促肿瘤、抗肿瘤和生物学功能。
